Raily Aesthetic Medicine International Holdings Limited (HKG:2135)
0.1190
0.00 (0.00%)
Nov 5, 2025, 9:55 AM HKT
HKG:2135 Revenue
Raily Aesthetic Medicine International Holdings had revenue of 84.60M CNY in the half year ending June 30, 2025, a decrease of -13.30%. This brings the company's revenue in the last twelve months to 166.47M, down -20.46% year-over-year. In the year 2024, Raily Aesthetic Medicine International Holdings had annual revenue of 199.34M with 5.26% growth.
Revenue (ttm)
166.47M CNY
Revenue Growth
-20.46%
P/S Ratio
0.36
Revenue / Employee
574.02K CNY
Employees
290
Market Cap
66.29M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 199.34M | 9.96M | 5.26% |
| Dec 31, 2023 | 189.38M | 24.86M | 15.11% |
| Dec 31, 2022 | 164.52M | -23.85M | -12.66% |
| Dec 31, 2021 | 188.37M | 23.82M | 14.48% |
| Dec 31, 2020 | 164.55M | -26.61M | -13.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |